Adverse events: Fatigue- 55%; Abdominal pain- 34%; Nausea- 19%; Grade 3/4 hyperbilirubinemia- 13%. Independent predictors of survival: Performance status, < 25% tumor burden, no extrahepatic metastases, albumin > 3 g/dl, and no more than two lines of chemotherapy. The gene discussed is ALB; the disease is Hyperbilirubinemia.